Items Tagged ‘checkpoint inhibitor’

May 16, 2018

PARP – Checkpoint Inhibitor Combo Promising in Ovarian Cancer

By

CancerConnect News: The combination of a PARP inhibitor and a checkpoint inhibitor appears promising as treatment for patients with ovarian cancer, according to results of a clinical study reported at the 2018 Society for Gynecologic Oncology Annual Meeting on Women’s Cancer in New Orleans, Louisiana.  Preliminary results from the study suggest that the combination could provide meaningful […]

View full entry

Tags: checkpoint inhibitor, News, Ovarian Cancer, PARP Inhibitors, PD-1, Precision Cancer Medicine


February 15, 2018

Keytruda Immunotherapy Appears Active for Treatment of Liver Cancer

By

CancerConnect News:  According to the results of a study presented at the recent gastrointestinal cancer symposia, Keytruda (pembrolizumab) is an active treatment for advanced liver cancer in patients who have already been treated with Nexavar (sorafenib).1 About Liver Cancer Liver cancer, or hepatocellular carcinoma (HCC), is the second most common cause of cancer-related deaths worldwide.2,3 […]

View full entry

Tags: checkpoint inhibitor, hepatocellular cancer, immunotherapy, keytruda, Liver Cancer, News, pembrolizumab, Precision Cancer Medicine


February 13, 2018

Keytruda Promising in PD-L1 Esophageal Cancer

By

CancerConnect News: The checkpoint inhibitor Keytruda (pembrolizumab) has been reported to produce an overall response rate of 30% in patients with PD-L1–positive, advanced esophageal cancer.1 About Keytruda Keytruda is a monoclonal antibody that helps to restore the body’s immune system in fighting cancer. It creates its anti-cancer effects by blocking a specific protein used by cancer […]

View full entry

Tags: checkpoint inhibitor, Esophageal Cancer, gastroesophageal junction cancer, immunotherapy, keytruda, News, pembrolizumab, Precision Cancer Medicine


January 23, 2018

Keytruda Effective in Patients with Relapsed or Refractory Lymphoma

By

CancerConnect News: Findings from the KEYNOTE-170 clinical trial Presented at the 59th American Society of Hematology (ASH) Annual Meeting suggest that the novel immunotherapy medication keytruda® (pembrolizumab) represents a new treatment option for non-Hodgkin lymphoma. About Keytruda Keytruda is a monoclonal antibody that helps to restore the body’s immune system in fighting cancer. It creates its […]

View full entry

Tags: checkpoint inhibitor, keytruda, Mediastinal Large B-Cell Lymphoma, News, non-hodgkin lymphoma, Non-Hodgkin's Lymphoma, pembrolizumab, Precision Cancer Medicine


January 17, 2018

Keytruda in Combination with Alimta and Platinum Chemotherapy Improves Survival in Non Small Cell Lung Cancer

By

CancerConnect News: Keytruda (pembrolizumab) is the first PD1 Inhibitor to demonstrate improved overall survival when combined with chemotherapy as primary treatment for metastatic non-squamous non-small cell lung cancer (NSCLC). The KEYNOTE-189 clinical trial evaluated Keytruda in combination with Alimta (pemetrexed) and cisplatin or carboplatin chemotherapy for the first-line treatment of patients with NSCLC. Interim results […]

View full entry

Tags: checkpoint inhibitor, immunotherapy, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, non-squamous, nsclc, PD1 Inhibitor, pembrolizumab, Precision Cancer Medicine


November 9, 2017

Checkpoint Inhibitors Improve Outcomes of Renal Cell Cancer

By

Opdivo (nivolumab) a novel “checkpoint” inhibitor immunotherapy has been demonstrated to produce superior three year survival benefit for patients with previously treated advanced renal cell carcinoma (RCC).1 Treatment options for RCC continue to expand and are associated with improved outcomes. About Renal Cell Carcinoma Renal cell carcinoma accounts for more than 100,000 deaths worldwide each […]

View full entry

Tags: afinitor, checkpoint inhibitor, everolimus, immunotherapy, metastatic kidney cancer, News, opdivo, PD-1, Precision Cancer Medicine, Renal Cancer


October 17, 2017

Imfinzi Improves Survival in Stage 3 Non Small Cell Lung Cancer

By

Immunotherapy could be the new standard of care in patients with non-small cell lung cancer (NSCLC).  The novel immunotherapy checkpoint inhibitors Keytruda® (pembrolizumab) and Opdivo (nivolumab) are already standard of care for advanced NSCLC.1   A recently published study has demonstrated that patients with earlier stage III, locally advanced NSCLC may benefit from anther checkpoint inhibitor Imfinzi […]

View full entry

Tags: checkpoint inhibitor, durvalumab, Imfinzi, immunotherapy, keytruda, locally advanced NSCLC, Lung Cancer, News, nivolumab, opdivo, pembrolizumab, Precision Cancer Medicine


October 12, 2017

Immunotherapy Active Against Triple-Negative Breast Cancer

By

October is breast cancer awareness month and patients with triple-negative breast cancer (TNBC) should be aware that data from two clinical trials provide additional evidence that they may derive benefit from checkpoint inhibitor therapy.1-4 About Triple Negative Breast Cancer Approximately 12% of breast cancers are triple-negative breast cancers, meaning that they are estrogen-receptor negative (ER-), […]

View full entry

Tags: atezolizumab, Breast Cancer, checkpoint inhibitor, immunotherapy, keytruda, News, PD-1, pembrolizumab, Precision Cancer Medicine, Tecentriq, Triple Negative Breast Cancer


September 25, 2017

The US Food and Drug Administration has Expanded the Approval of the Precision Cancer Medicine Keytruda for Treatment of Gastric Cancer

By

Keytruda (Pembrolizumab) is now indicated for patients with recurrent locally advanced or metastatic gastric or gastro-esophogeal junction adenocarcinoma. Patients eligible for keytruda therapy under this new indication must have PD-L1-expressing tumors, and must demonstrate disease progression after two or more prior lines of therapy – including fluoropyrimidine- and platinum-containing chemotherapy and, in some cases, HER2/neu-targeted […]

View full entry

Tags: checkpoint inhibitor, Esophageal Cancer, Gastric Cancer, gastro-esophogeal junction cancer, keytruda, metastatic gastric, News, pembrolizumab, Precision Cancer Medicine